Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.88, $0.02 better than the analyst estimate of $1.86. Revenue for the quarter came in at $805.5 million versus the consensus estimate of $802.45 million.

GUIDANCE:

Neurocrine Biosciences sees FY2026 revenue of $2.7-2.8 billion, versus the consensus of $3.41 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.